Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993 Jul;52(7):531-3
Date
07/01/1993Pubmed ID
8346981Pubmed Central ID
PMC1005093DOI
10.1136/ard.52.7.531Scopus ID
2-s2.0-0027220102 (requires institutional sign-in at Scopus site) 101 CitationsAbstract
OBJECTIVES: Although case reports and some patient series suggest an increased risk of cancer among patients with scleroderma, there are no population based studies to support this association. A population based follow up study was therefore carried out of 233 patients with scleroderma from the six-county Uppsala health care region of Sweden for the time period 1955-84.
METHODS: Using the inpatient registry for the Uppsala health care region, all patients with scleroderma were identified. Their unique identification codes were then used to perform a record linkage with the National Cancer Registry. Expected cancer rates were determined using the age and gender specific rates for the Uppsala health care region.
RESULTS: The standardised incidence ratio (SIR) for all cancers among these patients was significantly increased (SIR = 2.4; 95% CI = 1.5 to 3.6). The SIRs for lung cancer (SIR = 7.8; 95% CI = 2.5 to 18.2) and non-Hodgkin's lymphoma (SIR = 9.6; 95% CI = 1.1 to 34.5) were also significantly increased. Excluding patients who were diagnosed with cancer within a year of their scleroderma diagnosis resulted in similar findings, though the SIR for non-Hodgkin's lymphoma was no longer statistically significant.
CONCLUSIONS: Larger population based investigations of cancer risk among patients with scleroderma are needed to confirm these initial findings and to evaluate in greater detail possible cancer risk among these patients.
Author List
Rosenthal AK, McLaughlin JK, Linet MS, Persson IAuthor
Ann K. Rosenthal MD Associate Dean, Chief, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AgedCohort Studies
Female
Follow-Up Studies
Humans
Incidence
Lung Neoplasms
Lymphoma, Non-Hodgkin
Male
Middle Aged
Neoplasms
Risk Factors
Scleroderma, Systemic
Sweden